MERCK & CO, INC. for MERCK & CO INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 21, 2020 | $1,020,000 | Replaced |
| 4th Quarter - Amendment (this page) | Jan 22, 2020 | $1,020,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Agriculture AGR
Funding levels for the Center for Veterinary Biologics in the Animal and Plant Health Inspection Service at the United State Department of Agriculture.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRADLEY ALLEN ROSSIN | — |
Taxation/Internal Revenue Code TAX
Tax Reform, Generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| COURTNEY LEE-ASHLEY | — |
| BRADLEY ALLEN ROSSIN | — |
Copyright/Patent/Trademark CPT
Issues relating to, Intellectual Property; US-Mexico-Canada Agreement; US-China trade; Patents/IP; Market exclusivity.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FILIPPONE | — |
| COURTNEY LEE-ASHLEY | — |
| COREY MALMGREN | — |
| BRADLEY ALLEN ROSSIN | — |
| ELIZABETH SCHWARTZ | — |
Health Issues HCR
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Affordable Care Act; Vaccines; Women's Health; Average Manufacturer Price (AMP) CAP repeal; Ebola; Antibiotics.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN DARLING | — |
| ROBERT FILIPPONE | — |
| COURTNEY LEE-ASHLEY | — |
| COREY MALMGREN | — |
| BRADLEY ALLEN ROSSIN | — |
| ELIZABETH SCHWARTZ | — |
Medicare/Medicaid MMM
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019 S. 1437, Drug-price Transparency in Communications (DTC) Act Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid Innovation; Medicaid Part D.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN DARLING | — |
| ROBERT FILIPPONE | — |
| COURTNEY LEE-ASHLEY | — |
| COREY MALMGREN | — |
| BRADLEY ALLEN ROSSIN | — |
| ELIZABETH SCHWARTZ | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.